| Characteristic . | Adjusted OR . | 95% CI . | P-Valuea . |
|---|---|---|---|
| Bridge to decisionb (reference: bridge to transplantation/bridge to recovery) | 13.5 | 2.5–93.1 | 0.004 |
| Weight <5 kg | 6.8 | 1.4–37.2 | 0.021 |
| Bilirubin >34 μmol/l (>2 mg/dl) | 5.0 | 1.4–18.5 | 0.013 |
| Diagnosis CHD/otherb (reference: cardiomyopathy/myocarditis) | 3.4 | 1.2–10.2 | 0.025 |
| Previous cardiac arrest | 2.7 | 1.0–8.0 | 0.063 |
| INTERMACS patient profile 1 (reference: INTERMACS patient profile >1) | 2.5 | 0.6–10.6 | 0.190 |
| ECMOb | 1.8 | 0.5–6.5 | 0.369 |
| Renal replacement therapyb | 1.8 | 0.6–6.1 | 0.315 |
| Characteristic . | Adjusted OR . | 95% CI . | P-Valuea . |
|---|---|---|---|
| Bridge to decisionb (reference: bridge to transplantation/bridge to recovery) | 13.5 | 2.5–93.1 | 0.004 |
| Weight <5 kg | 6.8 | 1.4–37.2 | 0.021 |
| Bilirubin >34 μmol/l (>2 mg/dl) | 5.0 | 1.4–18.5 | 0.013 |
| Diagnosis CHD/otherb (reference: cardiomyopathy/myocarditis) | 3.4 | 1.2–10.2 | 0.025 |
| Previous cardiac arrest | 2.7 | 1.0–8.0 | 0.063 |
| INTERMACS patient profile 1 (reference: INTERMACS patient profile >1) | 2.5 | 0.6–10.6 | 0.190 |
| ECMOb | 1.8 | 0.5–6.5 | 0.369 |
| Renal replacement therapyb | 1.8 | 0.6–6.1 | 0.315 |
Risk factors present at VAD implantation. Patients with ongoing support at the end of the study period (n = 6) and patients with missing bilirubin values (n = 9) were excluded (n = 105).
Multivariable logistic regression with augmented backward elimination. Variables considered for inclusion: treating hospital, era (2006–2010, 2011–2015, 2016–2020), device type (paracorporeal pulsatile, paracorporeal continuous or both), support type (left ventricular assist device, biventricular assist device or right ventricular assist device), sex, weight (<5 vs ≥5 kg), INTERMACS patient profile 1 vs >1, bilirubin level previous to VAD implantation (>34 vs ≤34 μmol/l) and previous cardiac arrest.
Variables forced in the model.
CHD: congenital heart disease; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; INTERMACS: Interagency Registry for Mechanical Circulatory Support; OR: odds ratio.
| Characteristic . | Adjusted OR . | 95% CI . | P-Valuea . |
|---|---|---|---|
| Bridge to decisionb (reference: bridge to transplantation/bridge to recovery) | 13.5 | 2.5–93.1 | 0.004 |
| Weight <5 kg | 6.8 | 1.4–37.2 | 0.021 |
| Bilirubin >34 μmol/l (>2 mg/dl) | 5.0 | 1.4–18.5 | 0.013 |
| Diagnosis CHD/otherb (reference: cardiomyopathy/myocarditis) | 3.4 | 1.2–10.2 | 0.025 |
| Previous cardiac arrest | 2.7 | 1.0–8.0 | 0.063 |
| INTERMACS patient profile 1 (reference: INTERMACS patient profile >1) | 2.5 | 0.6–10.6 | 0.190 |
| ECMOb | 1.8 | 0.5–6.5 | 0.369 |
| Renal replacement therapyb | 1.8 | 0.6–6.1 | 0.315 |
| Characteristic . | Adjusted OR . | 95% CI . | P-Valuea . |
|---|---|---|---|
| Bridge to decisionb (reference: bridge to transplantation/bridge to recovery) | 13.5 | 2.5–93.1 | 0.004 |
| Weight <5 kg | 6.8 | 1.4–37.2 | 0.021 |
| Bilirubin >34 μmol/l (>2 mg/dl) | 5.0 | 1.4–18.5 | 0.013 |
| Diagnosis CHD/otherb (reference: cardiomyopathy/myocarditis) | 3.4 | 1.2–10.2 | 0.025 |
| Previous cardiac arrest | 2.7 | 1.0–8.0 | 0.063 |
| INTERMACS patient profile 1 (reference: INTERMACS patient profile >1) | 2.5 | 0.6–10.6 | 0.190 |
| ECMOb | 1.8 | 0.5–6.5 | 0.369 |
| Renal replacement therapyb | 1.8 | 0.6–6.1 | 0.315 |
Risk factors present at VAD implantation. Patients with ongoing support at the end of the study period (n = 6) and patients with missing bilirubin values (n = 9) were excluded (n = 105).
Multivariable logistic regression with augmented backward elimination. Variables considered for inclusion: treating hospital, era (2006–2010, 2011–2015, 2016–2020), device type (paracorporeal pulsatile, paracorporeal continuous or both), support type (left ventricular assist device, biventricular assist device or right ventricular assist device), sex, weight (<5 vs ≥5 kg), INTERMACS patient profile 1 vs >1, bilirubin level previous to VAD implantation (>34 vs ≤34 μmol/l) and previous cardiac arrest.
Variables forced in the model.
CHD: congenital heart disease; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; INTERMACS: Interagency Registry for Mechanical Circulatory Support; OR: odds ratio.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
